-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $48

Benzinga·12/02/2025 18:02:41
Listen to the news
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $40 to $48.